Multiple Myeloma: Expression of Nucleoside Transporters on Malignant Plasma Cells and Their Relationship to Cellular Proliferation

References

• Kwong F. Y. P., Davies A., Tse C. M., Young J. D., Henderson P. J. F., Balwin S. A. Purification of human erythrocyte nucleoside transporter by immunoaffinity chromatography. Biochem. J. 1988; 255: 243–249
   PubMed Web of Science ®Google Scholar
• White J. C., Rathmell J. P., Capizzi R. L. Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells. J. Clin. Invest. 1987; 79: 380–387
   PubMed Web of Science ®Google Scholar
• Wiley J. S., Jones S. P., Sawyer W. H., Paterson A. R. P. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J. Clin. Invest. 1982; 69: 479–489
   PubMed Web of Science ®Google Scholar
• Wiley J. S., Jones S. P., Sawyer W. H. Cytosine arabinoside transport by human leukaemic cells. Eur. J. Clin. Oncol. 1983; 19(8)1067–1074
   PubMedGoogle Scholar
• Wiley J. S., Taupin J., Jamieson G. P., Snook M., Sawyer W. H., Finch L. R. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J. Clin. Invest. 1985; 75: 632–645
   PubMed Web of Science ®Google Scholar
• Wiley J. S., Snook M. B., Jamieson G. P. Nucleoside transport in acute leukaemia and lymphoma: close relation to proliferative rate. Br. J. Haematol. 1989; 71: 203–207
   PubMed Web of Science ®Google Scholar
• Agbanyo F. R., Vijayalakshmi D., Craik J. D., Gati W. P., McAdam D. P., Asakura J., Robins M. J., Paterson A. R. P., Cass C. E. 5′-S-(2-Aminoethyl)-W6-(4-nitrobenzyl)-5′-thioadenosine (SAENTA), a novel ligand with high affinity for polypeptides associated with nucleoside transport. Biochem. J. 1990; 270: 605–614
   PubMed Web of Science ®Google Scholar
• Jamieson G. P., Brocklebank A. M., Snook M. B., Sawyer W. H., Buolamwini J. K., Paterson A. R. P., Wiley J. S. Flow cytometric quantitation of equilibrative inhibitor-sensitive nucleoside transporter sites on human leukemic cells. Cytometry 1993; 14: 32–38
   PubMedGoogle Scholar
• Wiley J. S., Brocklebank A. M., Snook G. P., Sawyer W. H., Craik J. D., Cass C. E., Robins M. J., McAdam D. P., Paterson A. R. P. A new fluorescent probe for the equilibrative inhibitor-sensitive nucleoside transporter 5′-S-(2-Aminoethy 1)-N6-(4-nitrobenzy 1)-5′ -thioadenoside (SAENTA)-x2-fluorescein. Biochem. J. 1991; 273: 667–672
   PubMed Web of Science ®Google Scholar
• Cass C. E., Dahlig E., Lau E. Y., Lynch T. P., Paterson A. R. P. Fluctuations in nucleoside uptake and binding of the inhibitor of nucleoside transport, nitrobenzylthioinosine, during the replication cycle of HeLa cells. Cancer Res. 1979; 39: 1245–1252
   PubMed Web of Science ®Google Scholar
• Chen S. F., Cleaveland J. S., Hollman A. B., Wiemann M. C., Parks R. E., Stoeckler J. D. Changes in nucleoside transport sites in acute leukemia. Cancer Res. 1986; 46: 3449–3455
   PubMedGoogle Scholar
• Smith C. L., Pilarski L. M., Egerton M. L., Wiley J. S. Nucleoside transport and proliferative rate in human thymocytes and lymphocytes. Blood 1989; 74: 2038–2042
   PubMed Web of Science ®Google Scholar
• Wiley J. S., Snook M. B., Jamieson G. P. A controversy: Nucleoside transporter expression is correlated with proliferative rate in acute myeloid leukemia. Leukemia 1992; 6(5)486–488
   PubMed Web of Science ®Google Scholar
• Joshua D. E., Snowdon L., Gibson J., Hand H., Brown R., Warburton P., Kulkarni A., Vincent P., Young G., Gatenby P., Basten A., Kronenberg H. Multiple myeloma: Plateau phase revisited. Haematol. Rev. 1991; 5: 59–66
   Google Scholar
• Joshua D. E., Brown R., Ioannides R., Snowdon L., Gibson J., Warburton P., Nelson M., Francis, Kronenberg H. Multiparameter analysis of monitors of disease progression in myeloma: The role of serum thymidine kinase estimations. Oncol. (Life Sci. Adv. 1990; 9: 19–24
   Google Scholar
• Durie B. G. M., Salmon S. E., Moon T. E. Pretreatment, tumour mass, cell kinetics and prognosis in multiple myeloma. Blood 1980; 55: 364–372
   PubMed Web of Science ®Google Scholar
• Greipp P. R., Witzig T. E., Gonchoroff N. J. Immunofluorescent plasma cell labelling indices (LI) using a monoclonal antibody (BU-1). Am. J. Hematol. 1985; 20: 289–292
   PubMed Web of Science ®Google Scholar
• Joshua D. E., Ioannides R., Brown R. D., Francis S. E., Gibson J., Kronenberg H. Multiple myeloma: relationship between light chain isotype suppression, labelling index of plasma cells and CD38 expression of peripheral blood lymphocytes. Am. J. Hematol. 1988; 29: 5–11
   PubMed Web of Science ®Google Scholar
• Brown R. D., Joshua D. E., Ioannides R., Kronenberg H. Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma. Aust. N. Z. J. Med. 1989; 226–232
   PubMedGoogle Scholar
• Dodwell D. J., McGill I. G. The treatment of poor prognosis myelomatosis with a cytosine arabinoside containing combination. Hematol. Oncol. 1989; 7(4)295–296
   PubMed Web of Science ®Google Scholar
• Powell B. L., White J. C., Gregory B. W., Brockschmidt J. K., Rhinehardt-Clark A., Lyerly E. S., Chorley H. M., Capizzi R. L. S-phase fraction is not correlated with nucleoside transport in acute myeloid leukemia cells. Leukemia 1991; 5(7)598–601
   PubMed Web of Science ®Google Scholar
• Wiley J. S., Cebon J., Woodruff R., Jamieson G. P., Snook M. B., McKendrick J., Szer J., Gibson J., Sheridan W., Brocklebank A., Paterson A. R. P. Assessment of proliferative responses to GM-CSF in acute myeloid leukemia using a fluorescent ligand for the nucleoside transporter. Leukemia 1993, In press
   Web of Science ®Google Scholar
• Boccadoro M., Gavarotti P., Fossati G., Pileri A., Mar-Mont F, Neretto G., Gallamini A., Volta C., Tribalto M., Testa M. G., Amadori S., Mandelli F., Durie B. G. M. Low plasma cell 3[H]-thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: A reliable indicator of patients not requiring therapy. Br. J. Haematol. 1984; 58: 689–696
   PubMed Web of Science ®Google Scholar
• Greipp P. R., Kyle R. A. Clinical, morphological and cell kinetic differences amoung multiple myeloma, monoclonal gammopathy of undetermined significance and smouldering multiple myeloma. Blood 1983; 62: 166–171
   PubMed Web of Science ®Google Scholar
• Latreille J., Barlogie B., Johnston D., Drewinko B., Alexanian R. Ploidy and proliferative characteristics in monoclonal gammopathies. Blood 1982; 59: 43–51
   PubMed Web of Science ®Google Scholar
• Ruiz-Argiielles G. J., Katzmann J. A., Greipp P. R., Gon-Choroff N J, Garton J. P., Kyle R. A. Multiple myeloma: Circulating lymphocytes that express plasma cell antigens. Blood 1984; 64: 352–356
   PubMed Web of Science ®Google Scholar
• Potter M. Perspectives on the origins of multiple myeloma and plasmacytomas in mice. Hematology/Oncology Clinics of North America, B. Barlogie. W. B. Saunders, Philadelphia 1992; 6: 211–224, 2
   Google Scholar
• Powell B. L., White J. C., Gregory B. W., Capizzi R. L. A controversy: Nucleoside transporter expression is correlated with proliferative rate in acute myeloid leukemia. Leukemia 1992; 6(5)486–488
   PubMed Web of Science ®Google Scholar
• Belt J. A., Schell M. J., Mirro J. A controversy: Nucleoside transporter expression is correlated with proliferative rate in acute myeloid leukemia. Leukemia 1992; 6(5)486–488
   PubMed Web of Science ®Google Scholar